OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial Board	124
Editorial Board	122
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	83
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	77
Editorial Board	75
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	53
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	53
Thiazide-induced hyponatremia	52
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	51
Menopausal hormone therapy for the management of osteoporosis	51
Genetics of pubertal timing	49
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	48
Coronavirus disease 2019 and vitamin D	46
Immune checkpoint inhibitor-related thyroid dysfunction	43
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	42
Regulation of bone mass: A splendid Orchestra	40
The role of androgens in transgender medicine	35
Editorial Board	35
Sexual health and contraception in the menopause journey	34
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	32
Editorial Board	31
Haematological actions of androgens	30
Remnant lipoprotein particles and cardiovascular disease risk	29
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	29
Cardiometabolic outcomes of early onset hypogonadism in males	29

Editorial Board	29
Metabolic complications and their mechanisms in patients with craniopharyngioma	28
Type 1 diabetes related to immune checkpoint inhibitors	27
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	27
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25
Non-oestrogen-based and complementary therapies for menopause	25
The effect of osteoporosis treatment on bone mass	24
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	24
Medullary thyroid cancer - An update	24
Pathophysiology of thyroid-associated orbitopathy	24
Radioiodine therapy in the different stages of differentiated thyroid cancer	24
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Immune checkpoint inhibitor-related hypophysitis	23
Hormone therapy for menopause and premature ovarian insufficiency	23
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	22
History of androgens and androgen action	22
The role of hormone therapy in urogenital health after menopause	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Editorial Board	20
Editorial Board	19
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	19
Localization in primary hyperparathyroidism	19
Safety of androgen therapy in men with prostate cancer	18
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	18
Hyponatraemic encephalopathy	18
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Editorial Board	18
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	17
Genotype-phenotype correlations in Graves’ disease	17
Mortality in craniopharyngiomas: Data from the last two decades	17
Editorial Board	17
Diagnostic algorithm of hyponatremia	17
Preface	16
Genetics of anti-Müllerian hormone and its signaling pathway	16
Care quality improvement in differences of sex development	16
Anaplastic thyroid cancer: An update	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
Hormone replacement in disorders of sex development, and long-term effects	15
Exercise and physical activity in individuals at risk of fracture	15
Chemokines in thyroid autoimmunity	14
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	13
Strategies for improving the knowledge of patients and carers	13
COVID-induced thyroid autoimmunity	13
Ectopic craniopharyngiomas	12

Preface	12
Addressing the social determinants of adverse outcomes in pregestational diabetes	12
Outcomes of pregnancies complicated by type 2 diabetes	12
The epidemiology of disorders of sex development	12
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
Covid-19 and endocrinology	11
Paraneoplastic autoimmune hypophysitis: An emerging concept	11
Editorial Board	11
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	11
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	11
Editorial Board	11
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	11
Editorial Board	11
Menopausal hormone therapy in women with medical conditions	10
New potential treatment options for syndrome of inappropriate antidiuresis	10
SARS-CoV-2 infection and its effects on the endocrine system	10
Surgical treatment of thyroid cancer: Established and novel approaches	10
Endocrine abnormality in paraneoplastic syndrome	9
Current medical treatment and perspective in gonadotroph tumors	9
Real-world value of cabergoline in the treatment of acromegaly	9
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
How best to monitor the specific side effects of medical treatments of Cushing’s disease	9
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	9
Quality of life in thyroid cancer	9
Androgen-based therapies in women	9
Long-term thionamide antithyroid treatment of Graves' disease	8
Management of patients with statin intolerance	8
Adolescent primary hyperparathyroidism	8
Genetics of 46,XY gonadal dysgenesis	8
Regulation of bone mass in endocrine diseases including diabetes	7
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	7
Burosumab: Current status and future prospects	7
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	7
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	7
Editorial Board	7
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	7
Pituitary and SARS CoV-2: An unremitting conundrum	6
Novel androgen therapies including selective androgen receptor modulators	6
Vitamin D deficiency or resistance and hypophosphatemia	6
COVID-19 vaccination and thyroiditis	6
Androgens part 2: Emerging areas	6
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	6
Traumatic brain injury and hypopituitarism	6
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	6
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Inherited fibroblast growth factor 23 excess	6
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	6
Tumor-induced osteomalacia: An overview	5
Hypothalamus-sparing surgery in craniopharyngiomas: Oncological and hypothalamic long-term outcomes	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Heritable hyperparathyroidism: Genetic insights and clinical implications	5
Morbidity and mortality in men: Role of androgens	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Pituitary dysfunction due to sports injuries	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Androgen therapy for women after menopause	5
Innovative therapeutics in acromegaly	5
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	5
Broader impact and outcome of human NR5A1/SF1 variants	5
New advances in menopause symptom management	5
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Genetics of cryptorchidism and testicular regression	4
Editorial Board	4
Editorial Board	4
Androgens, sports, and detection strategies for anabolic drug use	4
Primary hyperparathyroidism	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	4
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
The pathophysiology of hypophosphatemia	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4